Bausch Health Companies Inc. Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations
Bausch Health Companies Inc. (BHC) reported Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations of $2.00 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-19.
Financial Statements › Notes › Income Taxes › Income Tax Uncertainties
us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations · last filed 2026-02-19
- Bausch Health Companies Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2025 was $2.00M, a 88.89% decline from fiscal 2024.
- Bausch Health Companies Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2024 was $18.00M, a 800.00% increase from fiscal 2023.
- Bausch Health Companies Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2023 was $2.00M, a 97.65% decline from fiscal 2022.
- Bausch Health Companies Inc. unrecognized tax benefits, reduction resulting from lapse of applicable statute of limitations for fiscal 2022 was $85.00M, a 49.70% decline from fiscal 2021.
| Period end | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month | Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations 12 month as first filed |
|---|---|---|
| 2025-12-31 | $2.00M 10-K · filed 2026-02-19 | |
| 2024-12-31 | $18.00M 10-K · filed 2026-02-19 | $29.00M 10-K · filed 2025-02-20 |
| 2023-12-31 | $2.00M 10-K · filed 2026-02-19 | $4.00M 10-K · filed 2024-02-22 |
| 2022-12-31 | $85.00M 10-K · filed 2025-02-20 | |
| 2021-12-31 | $169.00M 10-K · filed 2024-02-22 | |
| 2020-12-31 | $5.00M 10-K · filed 2023-02-23 | |
| 2019-12-31 | $18.00M 8-K · filed 2022-05-11 | |
| 2018-12-31 | $6.00M 8-K · filed 2021-05-04 | |
| 2017-12-31 | $9.00M 10-K · filed 2020-02-19 | |
| 2016-12-31 | $13.00M 10-K · filed 2019-02-20 | |
| 2015-12-31 | $5.00M 8-K · filed 2018-08-10 | |
| 2014-12-31 | $8.00M 10-K · filed 2017-03-01 | $8.10M 10-K · filed 2015-02-25 |
| 2013-12-31 | $2.00M 10-K · filed 2016-04-29 | $2.04M 10-K · filed 2014-02-28 |
| 2012-12-31 | $2.00M 10-K · filed 2015-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |